Mira Pharmaceuticals Inc

Home
United States
Miami, FL
Mira Pharmaceuticals Inc

Advancing innovative oral therapeutics for neuropathic pain, inflammation, metabolic disorders, and oncology-related diseases.

09/30/2026

I’m looking forward to representing MIRA Pharmaceuticals (NASDAQ: $MIRA) at BioJapan 2026 in Yokohama, October 7–9.

We are entering an important period for MIRA. Following the completion of Phase 1 with Ketamir-2, our focus is now on site activation and initiating our Phase 2a study in chemotherapy-induced peripheral neuropathy (CIPN).

At the same time, we are building a broader pipeline with MIRA-55 in inflammatory pain and SKNY-1 in obesity.

Our objective at BioJapan is to meet with pharmaceutical and biotechnology companies interested in licensing, strategic partnerships and opportunities to help expand the global development potential of our programs.

I believe some of the most valuable partnerships begin with the right conversation.

We already have a strong schedule of meetings in Japan and look forward to building new relationships around MIRA’s pipeline and the opportunities ahead.

If you will be attending BioJapan and see potential alignment, I would be pleased to connect.

BioJapan 2026 | Yokohama, Japan | October 7–9

09/28/2026

$MIRA, I’m proud that Dr. Itzchak Angel, our Chief Scientific Advisor, will serve as a Keynote Speaker and Plenary Lecturer at the International Conference on Addiction and Psychiatry in Tokyo.

On October 6 from 9:00–9:40 a.m. local time, Dr. Angel will present a clinical development update on Ketamir-2, including our Phase 1 findings and its advancement toward Phase 2a in chemotherapy-induced peripheral neuropathy (CIPN).

From Tokyo, we head to Yokohama for BioJapan 2026, October 7–9.

For me, BioJapan is about taking the next step: engaging directly with global pharmaceutical and biotechnology companies around potential strategic partnerships, licensing opportunities, and collaborations across MIRA’s pipeline.

With Ketamir-2 advancing clinically and additional programs progressing across inflammatory pain and obesity, this is an important time to expand those conversations internationally.

I look forward to representing MIRA in Japan and meeting with potential partners from around the world.

American Cancer Society, Prezentis, International Association for the Study of Pain, American Academy of Pain Medicine, American Society of Clinical Oncology (ASCO), The Foundation for Peripheral Neuropathy, The National Institutes of Health, Japan Bioindustry Association

06/19/2026

$MIRA | Advancing Ketamir-2 Toward Phase 2a

MIRA Pharmaceuticals has submitted its Phase 2a clinical study plan to the FDA for Ketamir-2, our investigational therapy being developed for chemotherapy-induced peripheral neuropathy (CIPN).

CIPN affects an estimated 30–40% of patients receiving chemotherapy and can significantly impact quality of life. Despite its prevalence, there are currently no FDA-approved therapies specifically developed for this condition.
Ketamir-2 has completed Phase 1 clinical development with no serious adverse events.

The submission of the Phase 2a study plan represents an important step in the clinical development process as we continue working to address a significant unmet medical need in oncology supportive care.

This post contains forward-looking statements. See our SEC filings for risk factors.

06/16/2026

$MIRA | MIRA Pharmaceuticals will be attending BIO International Convention in San Diego, June 22–25.

Ketamir-2 has successfully completed Phase 1 clinical development and is advancing toward Phase 2a evaluation in chemotherapy-induced peripheral neuropathy (CIPN), an area of significant unmet medical need with no FDA-approved therapies.

Program highlights:
• Once-daily oral administration
• DEA non-scheduled
• Patent-protected across major pharmaceutical markets
• Supported by completed Phase 1 clinical data

MIRA Pharmaceuticals is a NASDAQ-listed biotechnology company with a clean capital structure and is available for licensing, co-development, and strategic partnership discussions.

To schedule a meeting, please submit a request through the BIO Partnering Portal.

06/11/2026

$MIRA Prescribing gabapentin for CIPN is not a treatment decision. It is a concession that no better option exists.

For oncology patients dealing with chemo-induced nerve damage, the pharmacologic fallback is a drug approved for epilepsy and a drug approved for diabetic neuropathy. Neither was tested in CIPN at approval. Neither is FDA-approved for CIPN today. Patients are not getting care tailored to their condition.

They are getting the closest approximation medicine could find. Ketamir-2 is being built specifically for this population, from the ground up, with a mechanism designed for the biology of chemotherapy-induced nerve injury.

$MIRA

06/09/2026

$MIRA | Ketamir-2 Preclinical Data

Scientific findings carry greater weight when they are subjected to independent peer review and published in the scientific literature.

Preclinical data evaluating Ketamir-2 were published in Frontiers in Pharmacology, a peer-reviewed journal, where the compound demonstrated activity in established models of neuropathic pain and was compared against currently available therapies, including gabapentin and pregabalin.

These findings support the continued development of Ketamir-2 as a potential treatment for chemotherapy-induced peripheral neuropathy (CIPN).

Peer-reviewed. Published. Advancing toward the clinic.

$MIRA

06/04/2026

$MIRA | MIRA Pharmaceuticals will be attending the BIO International Convention in San Diego (June 22–25, 2026) and is actively scheduling partnering meetings through the BIO One-on-One Partnering™ portal.

Ketamir-2 continues advancing toward Phase 2a development in chemotherapy-induced peripheral neuropathy (CIPN) following positive Phase 1 clinical results across 56 healthy volunteers.

Ketamir-2 is a proprietary oral NMDA receptor modulator designed with:
• Favorable safety and tolerability
• Dose-proportional PK
• Once-daily oral administration potential
• DEA non-scheduled status

CIPN remains a significant unmet medical need with no FDA-approved therapies currently available.

MIRA believes Ketamir-2’s expanding clinical and intellectual property position may support future strategic licensing, co-development, and broader partnership opportunities.

Partnering meetings are now available through the BIO International partnering platform. Search “MIRA Pharmaceuticals” to request a meeting.

06/02/2026

$MIRA | SKNY-1 Weight Loss Data — What's Different About This One
With weight loss drugs dominating headlines, one question keeps coming up: what about lean muscle mass?
GLP-1 drugs — the current standard — are highly effective at reducing weight, but a growing body of clinical evidence shows they also reduce lean muscle mass, which has real implications for long-term metabolic health.
MIRA Pharmaceuticals' SKNY-1 preclinical data showed something worth noting:

• ~30% body weight reduction at the higher dose
• Reduction in total cholesterol and LDL
• Reduction in liver fat accumulation
• No significant reduction in whole-body density

That fourth point — no lean mass signal — is what makes this dataset worth paying attention to, even at this early preclinical stage.
SKNY-1 is an oral compound working through a completely different mechanism than GLP-1 drugs. More studies are needed before any clinical decisions. But the profile is differentiated — and it's asking the right questions.

📄 Full publication: https://loom.ly/pekcFjA
$MIRA $NASDAQ

06/01/2026

MIRA Pharmaceuticals ($MIRA) Secured Worldwide Rights for Ketamir-2!

Last week, MIRA Pharmaceuticals announced the expansion of its exclusive Ketamir-2 license from North American exclusivity to worldwide rights — now covering patent filings across the United States, Europe, China, Japan, Canada, Australia, India, Israel, Mexico, and South Korea.

Here's why it matters beyond the headline:
1. Ketamir-2 is advancing toward Phase 2a in chemotherapy-induced peripheral neuropathy — an indication affecting an estimated 30–40% of chemotherapy patients for which there are currently no FDA-approved treatments. The first approved therapy in CIPN doesn't enter a competitive market. It creates one.
2. Worldwide IP rights mean that commercial opportunity — and any future licensing, co-development, or partnership discussion around it — is now backed by a global patent footprint spanning the world's largest pharmaceutical markets.
3. Phase 1 is complete. 56 healthy volunteers. Zero serious adverse events. Adverse events were higher in the placebo group than in the Ketamir-2-treated group.

Phase 2a protocol submission to the FDA is on deck.
📋 Full PR: https://loom.ly/voWAiIc

$MIRA |

05/28/2026

$MIRA | MIRA Pharmaceuticals — Positive Phase 1 Results for Ketamir-2
MIRA Pharmaceuticals today reported positive unblinded Phase 1 clinical results for Ketamir-2, its oral drug candidate for chemotherapy-induced peripheral neuropathy (CIPN) — nerve damage caused by cancer treatment that affects 30–40% of chemotherapy patients and has zero FDA-approved treatments.

Here's what Phase 1 showed across 56 healthy volunteers:

Safety & Tolerability
• Zero serious adverse events
• Zero dose-limiting toxicities
• Zero withdrawals — all participants completed the study
• Adverse events were predominantly mild — and the incidence was higher in the placebo group than in the Ketamir-2-treated group

Phase 2a in CIPN patients is the next step — submitting the protocol to the FDA under an active IND.
For the millions of cancer patients dealing with lasting nerve damage from chemotherapy and no approved treatment options, this is a program worth watching.

📋 Full PR: https://loom.ly/ZmjC1ME
$MIRA $NASDAQ

Address

1200 Brickell Avenue Suite 1950#1183
Miami, FL
33133

Website

https://mirapharmaceuticals.com/

Alerts

Be the first to know and let us send you an email when Mira Pharmaceuticals Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Mira Pharmaceuticals Inc:

Christina Archer Consulting

Want your business to be the top-listed business in Miami?